C4 Therapeutics (CCCC) Depreciation & Amortization (CF) (2019 - 2026)
C4 Therapeutics has reported Depreciation & Amortization (CF) over the past 8 years, most recently at $404000.0 for Q1 2026.
- For Q1 2026, Depreciation & Amortization (CF) fell 11.4% year-over-year to $404000.0; the TTM value through Mar 2026 reached $1.9 million, up 4.44%, while the annual FY2025 figure was $2.0 million, 7.76% up from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 was $404000.0 at C4 Therapeutics, down from $428000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $615000.0 in Q2 2025 and troughed at $300000.0 in Q1 2022.
- A 5-year average of $452176.5 and a median of $448000.0 in 2024 define the central range for Depreciation & Amortization (CF).
- Biggest five-year swings in Depreciation & Amortization (CF): tumbled 33.48% in 2022 and later surged 66.67% in 2023.
- Year by year, Depreciation & Amortization (CF) stood at $521000.0 in 2022, then dropped by 17.47% to $430000.0 in 2023, then rose by 11.63% to $480000.0 in 2024, then fell by 10.83% to $428000.0 in 2025, then dropped by 5.61% to $404000.0 in 2026.
- Business Quant data shows Depreciation & Amortization (CF) for CCCC at $404000.0 in Q1 2026, $428000.0 in Q4 2025, and $460000.0 in Q3 2025.